175791-53-4

Basic information

• Product Name: 5-Iodo-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 5-Iodo-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 175791-53-4
• Molecular Formula: C6H4IN3
• Molecular Weight: 245.02053
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 175791-53-4.mol

Chemical Properties

• Boiling Point: 260℃
• Flash Point: 111℃
• Appearance: /
• Density: 2.36
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.98±0.20(Predicted)
• CAS DataBase Reference: 5-Iodo-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Iodo-7H-pyrrolo[2,3-d]pyrimidine(175791-53-4)
• EPA Substance Registry System: 5-Iodo-7H-pyrrolo[2,3-d]pyrimidine(175791-53-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 175791-53-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Iodo-7H-pyrrolo[2,3-d]pyrimidine is used as a key intermediate in the synthesis of various drugs and pharmaceuticals. Its chemical properties make it a valuable component in the development of new medications, contributing to the advancement of healthcare and treatment options.
Used in Chemical Research:
5-Iodo-7H-pyrrolo[2,3-d]pyrimidine is employed as a research compound in various chemical studies. Its reactivity and structural characteristics allow scientists to explore its potential applications and interactions with other compounds, furthering our understanding of organic chemistry and its practical applications.
It is important to handle 5-Iodo-7H-pyrrolo[2,3-d]pyrimidine with care due to its potential chemical reactivity, ensuring safety in both research and pharmaceutical settings.

Upstream product

• 271-70-5 7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1596337-25-5 5-iodo-7-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 1596335-56-6 2-(4-chlorophenyl)-N-(6-{[7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl}pyrimidin-4-yl)acetamide 
• 1596335-36-2 2-(4-chlorophenyl)-N-[2-(7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)pyridin-4-yl]acetamide 
• 1596336-55-8 2-(4-cyanophenyl)-N-(6-methoxy-4-{[7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl}pyridin-2-yl)acetamide 
• 1596335-57-7 2-(3,4-dichlorophenyl)-N-{4-[(7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)carbonyl]pyridin-2-yl}acetamide 
• 1384953-47-2 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1384953-53-0 tert-butyl 5-(1-benzyl-1H-1,2,3-triazol-4-yl)pyrrolo[2,3-d]pyrimidine-7-carboxylate 
• 454685-88-2 5-cyanopyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acc

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The present invention relates to novel compounds that are CGRP receptor antagonists, processes for their preparation, to compositions containing them and to their use in the treatment of migraine, headache, and cluster headache.

INHIBITORS OF E1 ACTIVATING ENZYMES

This invention relates to compounds that inhibit El activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

Condensed heteroaromatic ring systems. Part 24. Synthesis of rigidin, a pyrrolo[2,3-d]pynmidine marine alkaloid

The marine alkaloid rigidin has been synthesized from 2,4-dimethoxy-7-phenylsulfonylpyrrolo[2,3-d]-pyrimidine. Lithiation of the pyrrolo[2,3-d]pyrimidine followed by electrophilic substitution with N,4-dimethoxy-N-methylbenzainide afforded a 6-(4-methoxy)